Scotiabank raised the firm’s price target on Apellis (APLS) to $22 from $20 and keeps a Sector Perform rating on the shares. The firm is constructive on the FDA’s approval of Empaveli, an immunosuppressant developed to treat paroxysmal nocturnal hemoglobinuria, and believes the company is in a good place to execute on the launch, the analyst tells investors. While the firm believes the commercial ramp of the drug may take more time than currently appreciated, Scotiabank remains positive on longer-term prospects and believes revenues in the outer years can grow to become meaningful.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Buy Rating for Apellis Pharmaceuticals Driven by FDA Approval and Promising Financial Projections for Empaveli
- Positive Outlook for Apellis Pharmaceuticals Following Empaveli Approval
- Cautious Optimism for Apellis Pharmaceuticals Amid Empaveli Approval and Market Challenges
- Apellis price target raised to $46 from $41 at Citi
- Apellis Pharmaceuticals: Buy Rating Driven by Empaveli’s Market Potential and Strong Growth Prospects